CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma
- 1 December 2014
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 37 (6) , 550-554
Abstract
Background: Carbohydrate antigen (CA) 19-9 is the most common serum biomarker used in pancreatic adenocarcinoma (PC). Elevated preoperative levels have been shown to correlate with more advanced stage, greater risk of unresectability, and overall worse survival. The prognostic value of CA 19-9 nonproduction, which is present in an estimated 5% to 15% of the population, is unclear. We sought to determine whether CA 19-9 nonproduction was associated with worse survival after PC resection. Methods: We retrospectively reviewed our institution’s prospective pancreatic database for all PC patients with documented preoperative CA 19-9 values who underwent resection with curative intent from March 1992 to August 2009. After excluding 10 perioperative deaths, 200 patients remained for analysis. Results: Mean and median follow-up was 23.3 and 16.1 months, respectively. Median survival in months for patients with preoperative CA 19-9 levels in U/mL by category was as follows: normal (5.1 to 36.9): 32, nonproduction (≤5): 21, mildly elevated (37 to 99.9): 35, highly elevated (100+): 16. Factors significantly associated with worse overall survival were: nonwhite race, nonproduction or highly elevated preoperative CA 19-9 (≥100 U/mL), estimated blood loss ≥1 L, tumor size (≥2 cm), lymph node-positivity, and advanced (3/4) histologic grade. On multivariate analysis, only CA 19-9 nonproduction or highly elevated production, estimated blood loss ≥1 L, advanced histologic grade, and node positivity remained significant in the final model. Conclusions: CA 19-9 nonproduction is not associated with improved survival after pancreatic cancer resection, as has previously been asserted, when compared with patients with normal and elevated levels.Keywords
This publication has 15 references indexed in Scilit:
- Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic CancerAnnals of Surgical Oncology, 2010
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant ChemoradiationAnnals of Surgical Oncology, 2010
- Long-Term Survival After Multidisciplinary Management of Resected Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2009
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinomaJournal of Hepato-Biliary-Pancreatic Surgery, 2007
- Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2004
- CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancerThe American Journal of Surgery, 1996
- Long-Term Survival After Curative Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 1996
- Lewis Phenotypes of American Caucasians, American Negroes and Their ChildrenVox Sanguinis, 1980